BioNTech continues pipeline buildout with WuXi antibody deal

11 Jan 2024
firstwordpharma.com
VaccineLicense out/inAcquisitionPhase 2
BioNTech’s burgeoning cancer portfolio could gain two more antibodies, thanks to a discovery deal the company signed Thursday with WuXi Biologics. Flush with cash from its successful COVID-19 vaccineCOVID-19 vaccine, BioNTech has been on a spending spree since late 2022 to bulk out its pipeline as vaccine revenues decline.
WuXi will receive $20 million upfront to discover two monoclonal antibodies (mAbs) against undisclosed targets for BioNTech. The Chinese CRDMO is also eligible for undisclosed research, development, regulatory and commercial milestones, plus tiered royalties.
The partnership is at least the sixth recent discovery or licensing-focused deal from BioNTech, spanning small molecule, mAb, bispecific, and antibody drug conjugate (ADC) modalities intended to treat cancer. The company also completed an acquisition of InstaDeep in July 2023 for about €500 million in cash, gaining its artificial intelligence-driven drug discovery and development platform.
The most recent deal came in November when BioNTech agreed to spend up to $1 billion to develop Biotheus’ bispecific antibody candidate PM8002. The experimental drug, which is currently being investigated in Phase II studies in patients with advanced solid tumours, consists of humanised anti-PD-L1 single heavy-chain variable domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations.
At the same time it announced the Biotheus collaboration, BioNTech had said it expects 2023 revenue from its COVID-19 vaccine Comirnaty of around €4 billion ($4.3 billion), down from an earlier forecast of about €5 billion.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.